Compare EBF & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | ASMB |
|---|---|---|
| Founded | 1909 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.9M | 442.9M |
| IPO Year | 1994 | 2010 |
| Metric | EBF | ASMB |
|---|---|---|
| Price | $20.26 | $28.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | ★ 138.1K | 112.0K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | 7.79 | ★ 91.78 |
| EPS | ★ 1.66 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | $12.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.30 | $13.70 |
| 52 Week High | $22.36 | $39.71 |
| Indicator | EBF | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 48.50 |
| Support Level | $20.10 | $26.50 |
| Resistance Level | $21.39 | $31.11 |
| Average True Range (ATR) | 0.40 | 1.81 |
| MACD | -0.01 | -0.32 |
| Stochastic Oscillator | 40.27 | 36.27 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.